takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

pharmafile | May 11, 2020 | News story | Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis 

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a maintenance treatment of moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD).

The decision was backed up by Phase 3 data showing positive safety and efficacy in moderate-to-severely active UC or CD patients that achieved clinical response after week six weeks following two intravenous doses of open-label vedolizumab.

Takeda’s Adam Zaeske, Head of GI Franchise, Europe and Canada Business Unit, remarked: “We are delighted that the European Commission has approved the subcutaneous formulation of Entyvio. This allows physicians and adult patients to choose the delivery method that works best for each individual patient. Takeda’s commitment to treating gastrointestinal disease means that we are always looking to innovate to provide further therapeutic options to better meet the needs of the patients we serve.”

The subcutaneous formulation will be available in pre-filled syringe and pen forms, Takeda confirmed, and regulatory approval is also being pursued in other regions around the world.

Matt Fellows

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …

Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results …

Latest content